We are live on ! Find out more
CNTA

Centessa Pharmaceuticals
CNTA

Delisted

CNTA was delisted on the 23rd of June, 2026.

Back to rankings

50 hedge funds and large institutions have $1.05B invested in Centessa Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

54.23% more ownership

Funds ownership: 0% → 54.23% (+54%)

Holders
50
Holders Change
+50
Holders Change %
–
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
50
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MVM
Medicxi Ventures Management
Jersey
+$421M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$134M
3
VVA
Vida Ventures Advisors
Massachusetts
+$92.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$47.3M
5
SB
Samsara BioCapital
California
+$36.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$2.22M +$2.35M +100,000 New
State of Wisconsin Investment Board
27
State of Wisconsin Investment Board
Wisconsin
$1.78M +$1.89M +80,381 New
AAA
28
Affinity Asset Advisors
New York
$1.49M +$1.57M +66,957 New
CCM
29
CAAS Capital Management
New York
$1.39M +$1.47M +62,500 New
BI
30
BVF Inc
California
$1.31M +$1.38M +58,900 New
Tudor Investment Corp
31
Tudor Investment Corp
Connecticut
$957K +$1.01M +43,079 New
Temasek Holdings
32
Temasek Holdings
Singapore
$926K +$980K +41,680 New
Blackstone Inc
33
Blackstone Inc
New York
$888K +$940K +40,000 New
Squarepoint
34
Squarepoint
New York
$839K +$888K +37,771 New
MWNA
35
Marshall Wace North America
New York
$760K +$804K +34,228 New
TD Asset Management
36
TD Asset Management
Ontario, Canada
$686K +$781K +33,252 New
GCM
37
Ghisallo Capital Management
Massachusetts
$555K +$588K +25,000 New
Northern Trust
38
Northern Trust
Illinois
$409K +$432K +18,400 New
BC
39
Brookfield Corp
Ontario, Canada
$409K +$433K +18,404 New
Two Sigma Investments
40
Two Sigma Investments
New York
$222K +$234K +9,973 New
Geode Capital Management
41
Geode Capital Management
Massachusetts
$211K +$224K +9,513 New
BlackRock
42
BlackRock
New York
$110K +$117K +4,992 New
Bank of America
43
Bank of America
North Carolina
$54K +$56.4K +2,398 New
JP Morgan Chase
44
JP Morgan Chase
New York
$47K +$49.1K +2,090 New
TRCT
45
Tower Research Capital (TRC)
New York
$24K +$25.3K +1,077 New
Citigroup
46
Citigroup
New York
$24K +$25.6K +1,091 New
PCM
47
Pinz Capital Management
New York
$20K +$21.2K +900 New
UBS Group
48
UBS Group
Switzerland
$15K +$15.9K +678 New
CSS
49
Cubist Systematic Strategies
Connecticut
$9K +$9.4K +400 New
US Bancorp
50
US Bancorp
Minnesota
– +$447 +19 New
1
2

CNTA Hedge Fund Activity: Q2 2021 in Review

50 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2021, worth a combined $1.05B.

Buyers outnumbered sellers: 50 funds opened new CNTA positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Medicxi Ventures Management, opening a new position worth an estimated $421M.

  • 50 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $1.05B of Centessa Pharmaceuticals stock for Q2 2021.
  • 50 funds opened new Centessa Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +50 holders.
  • The largest Centessa Pharmaceuticals buyer in Q2 2021 was Medicxi Ventures Management, an estimated $421M added.

Based on aggregated 13F filings for Q2 2021.